# Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome

> **NCT00527878** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 16 (actual)

## Conditions studied

- JOB's Syndrome
- Hyper-IgE Recurrent Infection Syndrome
- Immune Deficiency

## Interventions

- **DRUG:** Ranitidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00527878
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Failure to enroll adequate patient numbers due to small number of eligible patients
- **Last updated:** 2013-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527878, "Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00527878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*